Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583501 | 0.85 | MTNR1A (0.44) | DRD2DRD4DRD3MTNR1ASMN1; SMN2 | |
| SCHEMBL16309064 | 0.69 | SMN1; SMN2 (0.51) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL3579151 | 0.69 | MEN1 (0.41) | MTNR1AKDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL16309075 | 0.68 | SMN1; SMN2 (0.50) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL24712976 | 0.67 | SMN1; SMN2 (0.49) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL26537904 | 0.67 | SMN1; SMN2 (0.49) | DRD2DRD4DRD3SMN1; SMN2MAP2K1 | |
| SCHEMBL18863880 | 0.67 | ALDH1A1 (0.52) | DRD2DRD4DRD3SMN1; SMN2KDM4E | |
| SCHEMBL16309072 | 0.67 | SMN1; SMN2 (0.49) | DRD2DRD4DRD3SMN1; SMN2MAP2K1 | |
| SCHEMBL25780650 | 0.67 | SMN1; SMN2 (0.46) | DRD2DRD4DRD3SMN1; SMN2MAP2K1 | |
| SCHEMBL128266 | 0.67 | MTNR1A (0.47) | DRD2DRD4DRD3MTNR1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098513-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-2098513-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 00 | 2010-01-14 | — | — | US | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098513-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010038-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | DRD2 31/4885DRD4 181/4885DRD3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.